Transcripta Bio

🌟 An update on our exciting progress in learning and predicting the effects of small molecules on the transcriptome! 🌟 Discover how Transcripta Bio is leveraging artificial intelligence in an omics-first approach to accelerate drug discovery for transformative patient impact. Dive into our latest blog post to learn more about this cutting-edge approach: https://lnkd.in/gutx_knX

As part of Nature Portfolio’s Biopharma Dealmakers, Transcripta Bio was featured for its pioneering work in AI-powered innovation for drug discovery. The traditional drug discovery process of identifying the causal mechanism of a disease, a single molecular target, and a drug against the target is slow, expensive, and fraught with the fallout from failed hypotheses. Transcripta Bio is revolutionizing the drug discovery process by screening thousands of compounds across numerous root-cause genes simultaneously, drastically reducing both time and cost. #TranscriptaBio #Biopharmadealmakers #Innovation

We are featured in Meta's Llama community stories! Read about us here!

Characterizing collections of molecules is an important chemoinformatics task. Beyond annotating molecules by common descriptors, can we gain insight by leveraging LLMs for initial triage? Our prototype app, MolSifter, does just that! We've been using NVIDIA Healthcare MolMIM model — guided by our own perturbation predictions — to generate molecules with specific effects on gene expression. LLMs help by 1) orienting us to interesting patterns in a collection and 2) enabling chat-based analysis to gain deeper insight. We are continuously exploring and building tools like MolSifter to map the relationships between chemical structure and gene expression to discover powerful new therapies for patients.

It's great to hear NVIDIA giving us a shout-out on their blog! Read about us here

We are honored to be included in TIME 100 Most Influential Companies of 2024 for our work speeding drug discovery! The TIME list recognizes Transcripta Bio for “dramatically reducing the time and money it takes to discover drugs —not just for rare diseases, but for any drug that treats disease by changing gene expression." We are charting a faster path in AI drug discovery to improve people's lives worldwide, and we will continue to work tirelessly to achieve this. #TranscriptaBio #TIME100Companies #AIdrugdiscovery

This was an amazing opportunity for us, we had a great time.

It was an exciting day at the Nvidia Inception event! Big thanks to Chelsea Sumner, PharmD, Rph and Renee Y. for hosting such an amazing gathering at the Nvidia Campus. And of course, a highlight was Clayton Mellina and Christopher Moxham getting a photo op with the one and only Jensen Huang! #NvidiaInception #TechLeaders #AIdrugdiscovery

Excited to hear Isomorphic Labs and Weights & Biases talk about #machinelearning and #AIdrugdiscovery!

We were honored to invite Ashlee Vance to Transcripta Bio to share our story and how we are charting a faster path in drug discovery to create better lives for people around the world. After working tirelessly for the last two years and completing more than 200 million experiments in our labs, we are opening the aperture of drug discovery to impact countless patients and lives. We have already seen rapid proof of our platform from the early results across a number of rare diseases for which there are no current treatments. This will remain an important area of focus for us. However, there is so much more that we can do — hence our company’s new name. Thank you to our brilliant and inspiring advisor Carrie Rich for sharing your story and being on this journey with us.